Protocol Ledger

NCT06524544 · Phase III · RECRUITING

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Interventional Phase III clinical trial protocol NCT06524544 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-02 Enrollment: 320 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06524544
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)320 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06524544
Protocol FieldVerified Registry Value
NCT IdentifierNCT06524544
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment320 participants (ESTIMATED)
Registered Start Date2025-12-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI